Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Nov 27, 2026; 18(11): 122279
Published online Nov 27, 2026. doi: 10.4240/wjgs.122279
Published online Nov 27, 2026. doi: 10.4240/wjgs.122279
Construction and validation of a prognostic prediction model based on albumin-bilirubin grade after resection of hepatocellular carcinoma
Lu-Yi Cong, Ling-Yu Ma, DSA Operating Room, Affiliated Nantong Clinical College of Nantong University, Nantong First People’s Hospital, Nantong 226000, Jiangsu Province, China
Xin Hong, Department of Intervention, Affiliated Nantong Clinical College of Nantong University, Nantong First People’s Hospital, Nantong 226000, Jiangsu Province, China
Gui-Ling Geng, School of Nursing, Nantong University, Nantong 226000, Jiangsu Province, China
Ben-Fang Fan, Department of Nursing, Affiliated Nantong Clinical College of Nantong Univer
Author contributions: Cong LY conceived and designed the research, acquired data, performed statistical analysis, obtained funding, and drafted the manuscript; Geng GL contributed to data acquisition and critically revised the manuscript for important intellectual content; Hong X participated in data analysis and interpretation and assisted in securing funding; Fan BF and Ma LY contributed to data analysis, interpretation, and statistical analysis. All authors read and approved the final manuscript.
AI contribution statement: No AI tools were employed in the preparation of this manuscript. All content was written solely by the authors.
Supported by Nantong Municipal Health Research Project, No. QNZ2024017 and No. MS2022019.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Nantong First People’s Hospital (approval No. 2026-KT024-02).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Corresponding author: Ben-Fang Fan, Chief Nurse, Department of Nursing, Affiliated Nantong Clinical College of Nantong University, Nantong First People’s Hospital, No. 666 Shengli Road, Chongchuan District, Nantong 226000, Jiangsu Province, China.
Received: May 29, 2026
Revised: June 29, 2026
Accepted: July 28, 2026
Published online: November 27, 2026
Processing time: 176 Days and 18.3 Hours
Revised: June 29, 2026
Accepted: July 28, 2026
Published online: November 27, 2026
Processing time: 176 Days and 18.3 Hours
Core Tip
Core Tip: We proposed and validated a new predictive tool, the nomogram, to assess whether patients with hepatocellular carcinoma will experience recurrence and how long they will live after radical surgery. This tool uses the level of bilirubin (commonly known as albumin-bilirubin). At the same time, it also combines known tumor indicators such as age, tumor size, number of tumors, and levels of alpha-fetoprotein. In this way, we can provide each patient with a more personalized and clinically relevant risk stratification, helping physicians better develop postoperative plans for patient monitoring and treatment.